News | Cath Lab | May 16, 2017

Early Treatment for NSTEMI Patients Shows Greater Rate of Survival

First time an analysis demonstrates reduction in mortality between early and late intervention

Early Treatment for NSTEMI Patients Shows Greater Rate of Survival

May 16, 2017 — An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within 24 hours of hospitalization showed an increased reduction in mortality, marking the first time this difference has been demonstrated. Results from “Outcomes of Early vs. Late Revascularization in Low and High-Risk Patients Hospitalized with Non-ST-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Surveillance Study” were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

NSTEMI is a type of heart attack that occurs when an artery is only partially blocked as opposed to a STEMI, where there is a complete blockage of the artery, making it the more severe of the two types.

While current guidelines recommend early intervention — defined as less than 24 hours — for STEMI patients, a delayed or late strategy — defined as between 24–72 hours — for NSTEMI is considered reasonable, unless there are extenuating circumstances, such as refractory angina or other conditions that put the patient in a higher risk category.

However, the optimum time for coronary revascularization of NSTEMI patients is under debate, according to Sameer Arora, M.D., of the University of North Carolina at Chapel Hill, Division of Cardiology and the study’s lead investigator. Evidence for current recommendations is based on clinical trials in controlled settings and selected patients.

Arora and his collaborators looked at data from the ARIC Community Surveillance Study, a large, ongoing investigation that began in 1987 involving 21 hospitals in four states: Maryland, Minnesota, Mississippi and North Carolina. Arora analyzed data from hospitalized NSTEMI patients undergoing coronary revascularization, and classified them as low- or high-risk, based on accepted risk scores. The survival benefit of an early revascularization (<24 hours after symptoms start) versus a late revascularization was analyzed using statistical models.

From 1987–2012, 9,960 patients were hospitalized with NSTEMI and underwent revascularization (67 percent percutaneous intervention, 28 percent bypass surgery and 5 percent thrombosis). Most were white (81 percent), male (69 percent), with a mean age of 62; approximately half (54 percent) were classified as low-risk. The overall 28-day mortality was 3 percent and most revascularizations (66 percent) were late.

After adjusting for confounding variables, such as diabetes and hypertension among others, early intervention was associated with an 87 percent lower mortality for low-risk patients (OR = 0.13; 95 percent CI: 0.02 – 0.93; p=0.04) and a 38 percent lower mortality for high-risk patients (OR = 0.62; 95 percent CI: 0.40 – 0.94; p=0.04). The association was consistent regardless of sex, race, or year of hospitalization.

Arora noted, “What we observed was both low- and high-risk NSTEMI patients who were treated within 24 hours of symptom onset had a 28-day survival benefit. To our knowledge, no clinical trials to date have reported a survival benefit related to early versus late revascularization.”

Arora reported no disclosures.

For more information: www.scaiscientificsessions.org

Related Content

Shockwave Launches Coronary Intravascular Lithotripsy in Europe
News | Cath Lab | May 30, 2018
Shockwave Medical recently announced the European commercial availability of Intravascular Lithotripsy (IVL) for...
FFR software on the GE Centricity CVIS. A trial from the 2018 EuroPCR meeting showed FFR improves long-term outcomes.
News | Cath Lab | May 29, 2018
May 29, 2018 — Ongoing controversy exists regarding the role of percutaneous coronary intervention (PCI) for stable c
SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018
Revised guidelines incorporating new data on discharge criteria for patients undergoing elective percutaneous coronary...
No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018
May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal c
Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018
May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is used
Recent Acquisitions Eroding Prices in Billion Dollar European Interventional Cardiology cath lab Market.
Feature | Cath Lab | May 07, 2018 | Simon Trinh and Jeffrey Wong
The European interventional cardiology market is currently valued at nearly $1.4 billion.
Videos | Cath Lab | May 07, 2018
Imran Ahmad, M.D., medical director of interventional cardiology, explains some of the new technologies his labs have
360 Photos | Cath Lab | April 20, 2018
A 360 degree view of the newest cath lab at Northwestern Medicine Central DuPage Hospital in Winfield, Ill., located
SCAI Announces Global Lecture Series for 2018 Scientific Sessions
News | Cath Lab | April 18, 2018
Many of the world’s leading interventional cardiologists and cardiovascular professionals will convene in San Diego,...
Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Figure 1. Serial coronary angiograms of the representative case treated with shockwave intravascular lithotripsy.

Feature | Cath Lab | April 16, 2018 | Azeem Latib, M.D.
Over the last decade, there have been considerable developments in procedural techniques and technology facilitating
Overlay Init